Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-25
2005-01-25
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06846836
ABSTRACT:
Compounds having the formula (I),are useful as inhibitors of mitochondrial F1F0ATP hydrolase, wherein R1-R8, X, A, Z, n and m are defined herein.
REFERENCES:
patent: 5610144 (1997-03-01), Capet et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5637602 (1997-06-01), Capet et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6194437 (2001-02-01), Horwell et al.
patent: 6423689 (2002-07-01), Booth et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 20030022890 (2003-01-01), Atwal et al.
patent: 2002173476 (2002-06-01), None
patent: WO 9204045 (1992-03-01), None
patent: WO 9301167 (1993-01-01), None
patent: WO 9535314 (1995-12-01), None
patent: WO 9965932 (1999-12-01), None
patent: WO 9967221 (1999-12-01), None
patent: WO 0001389 (2000-01-01), None
patent: WO 0009543 (2000-02-01), None
Moody, et al., European Journal of Pharmacology 409 (200) pp. 133-142.
Ashwood et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) pp. 2589-2594.
Eden et al., Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 21 pp. 2617-2622, no date available.
Ashwood, V. et al., “PD 176252—The First High Affinity Non-peptide Gastrin-Releasing Peptide (BB2) Receptor Antagonist”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2589-2594 (1998).
Bundgaard, H., “(C) Means to Enhance Penetration: (1) Prodrugs as a means to improve the delivery of peptide drugs”, Advanced Drug Delivery Reviews, vol. 8, pp. 1-38 (1992).
Cross, R.L. et al., “The Mode of Inhibition of Oxidative Phosphorylation by Efrapeptin (A23871): Evidence for an Alternating Site Mechanism for ATP Synthesis”, The Journal of Biological Chemistry, vol. 253, No. 4, pp. 4865-4873 (1978).
Eden, J.M. et al., “PD 165929—The First High Affinity Non-peptide Neuromedin-B (NMB) Receptor Selective Antagonist”, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 21, pp. 2617-2622 (1996).
Gasnier, F. et al., “Use of Percoll Gradients for Isolation of Human Placenta Mitochondria Suitable for Investigating Outer Membrane Proteins”, Analytical Biochemistry, vol. 212, pp. 173-178 (1993).
Kakeya, N. et al., “Studies on Prodrugs of Cephalosporins. I. Synthesis and Biological Properties of Glycyloxybenzoyloxymethyl and Glycylaminobenzoyloxymethy Esters of 7 β-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-methyl-3-cephem-4-carboxylic Acid”, Chem. Pharm. Bull., vol. 32, No. 2, pp. 692-698 (1984).
Matsuno-Yagi, A. et al., “Studies on the mechanism of oxidative phosphorylation: Effects of specific F0modifiers on ligand-induced conformation changes of F1”, Proc. Natl. Acad. Sci. USA, vol. 82, pp. 7550-7554 (1985).
Maughfling, E.J.R. et al., “Construction of chimeric human bombesin receptors to identify neuromedin B and gastrin-releasing peptide receptor binding sites”, Biochemical Society Transactions, vol. 25, p. 455S (1997).
Moody, T.W. et al., “Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells”, European Journal of Pharmacology, vol. 409, pp. 133-142 (2000).
Nielsen, N.M. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties”, Journal of Pharmaceutical Sciences, vol. 77, No. 4, pp. 285-298 (1988).
Pullman, M.E. et al., “Partial Resolution of the Enzymes Catalyzing Oxidative Phosphorylation”, The Journal of Biological Chemistry, vol. 235, No. 11, pp. 3322-3329 (1960).
Salomon, A.R. et al., “Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F0F1-ATPase”, PNAS, vol. 97, No. 26, pp. 14766-14771 (2000).
Hamann Lawrence G.
Pudzianowski Andrew T.
Bristol--Myers Squibb Company
Duncan Laurelee A.
Henley III Raymond J.
LandOfFree
N-substituted phenylurea inhibitors of mitochondrial F1F0... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted phenylurea inhibitors of mitochondrial F1F0..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted phenylurea inhibitors of mitochondrial F1F0... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3438279